Researchers revealed that the interleukin-17 inhibitor izokibep may be effective for treating patients with hidradenitis suppurativa, according to a report from Healio summarizing new findings presented by Papp et al at the 2023 AAD Annual Meeting. In a new phase IIb/III trial, researchers assigned 30 patients with moderate to severe hidradenitis suppurativa to receive 160 mg of izokibep per week. After 12 weeks of follow-up, the researchers discovered that 71%, 57%, 38%, and 33% of patients demonstrated Hidradenitis Suppurativa Clinical Responses of 50, 75, 90, and 100, respectively. “I think the results from [this study of] izokibep provide hope that there may be an additional, probably more effective therapy on the horizon,” concluded study author Kim A. Papp, MD, PhD, FRCPC, President and Director of Research at Probity Medical Research. The researchers hope to further examine the efficacy of izokibep in future phase III trials.
April 30, 2023